Good MorningEquity markets retreated on Wednesday after remarks from Fed Chief Jerome Powell failed to soothe the market. Mr. Powell says the committee may only hike rates one more time this year but also that inflation is yet to be tamed, and the committee is ready to hike rates again if needed. In addition, Mr. Powell seemed supportive of the financial system but failed to give explicit details of how the system could be backstopped.
The S&P 500 fell more than 1.6% at the end of the day, confirming the latest stock downtrend. The move confirms resistance at the 4,000 level and the 3rd lower consecutive peak since the bear market rally began. This could signify lower lows, but support may be present at 3,800. The only thing certain now is uncertainty, which will not be good for the market. In this light, 3,800 may only be a stopping point on the move to retest last year's lows. Featured: Do Not Buy Another AI Stock Before Seeing This (Ad) 
|
Consumer Discretionary | |
Ollie’s Bargain Outlet Holdings (NASDAQ: OLLI) is in the sweet spot. Manufacturers and retailers eager to shed unwanted inventory are helping to drive favorable conditions for Ollie’s and its chain of stores. The company has ample choice of inventory and the traffic to keep its invento... Read the Full Story |
|
From Our Partners | | MindWalk Holdings (NASDAQ: HYFT) is applying AI to drug discovery, and its customer base already includes 19 of the top 20 global pharmaceutical companies.
The company's HYFT technology maps roughly 660 million biological patterns and 25 billion relationships. Q1 fiscal 2027 revenue hit $3.8 million, with gross margin improving to 59 percent in its fifth consecutive quarter of year-over-year growth.
A new OpenFold3 deployment delivered about 5x faster antibody-antigen inference, and a $30 million revolving credit line, free of warrants or equity conversion, adds fuel for expansion. | | Take a closer look at HYFT before AI reshapes drug discovery. |
|
Technology | |
A look at the stock symbol of Samsara, Inc. (NYSE: IOT) defines what the company does, internet-of-things (IOT). The IoT comprises a network of connected devices that can be accessed remotely and communicate with each other, providing and transforming real-time and robust data. Samsara provides Io... Read the Full Story |
|
Consumer Discretionary | |
Shoe Carnival (NASDAQ: SCVL) is a multifaceted story that begins with a company with intrinsic value to consumers and a push toward digital. It ends with Salesforce.com (NASDAQ: CRM), the leading Customer Relationship Management firm. The combination has unlocked increased profitability, and t... Read the Full Story |
|
From Our Partners | | Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He points to a new AI project tied to Musk's Cybercab reveal.
Brown says Musk has opened major investment windows before, with PayPal, Tesla, and SpaceX marking milestones in tech history. He believes a fourth may open by October 30. | | See Jeff Brown's full analysis on Musk's new AI project |
|
Markets | |
Bitcoin (CRYPTO: BTC) seems to move with a mind of its own. At the time of writing it has just breached the $28,000 resistance level, a new high for 2023. Coincidentally, this rally times perfectly with the collapse of certain conduits of the fiat banking system, and gleefully defies the broad sel... Read the Full Story |
|
Consumer Discretionary | |
GameStop (NYSE: GME) is an interesting and exciting market to watch, but it is not a market for most investors to dabble with. The only thing that can be said is that volatility will reign supreme because the bulls and the bears have strong feelings about where its price should be. The analyst's s... Read the Full Story |
|
From Our Partners | | Forget Nvidia, Google, Amazon, and Microsoft. Jeff Brown says the next major AI opportunity has nothing to do with AI stocks at all.
Some of these AI assets have posted gains of 200%, 318%, and even 467% in 30 days or less, far outpacing Sandisk, 2026's top-performing AI stock, which rose just 10% in the same stretch.
Brown is highlighting five AI plays he believes carry even more upside potential, plus a free bonus pick. | | Click here to see the five AI plays and free bonus pick |
|
Consumer Discretionary | |
Nike, Inc’s (NASDAQ: NKE) FQ3/CQ1 surprise isn’t all that surprising, given results from others in the industry. Retailers like Dick’s Sporting Goods (NASDAQ: DKS), Hibbett Inc. (NASDAQ: HIBB), and Academy Sporting Goods and Outdoors (NASDAQ: ASO) all reported solid results with ... Read the Full Story |
|
Markets | |
Watch the Direxion Daily S&P 500 Biotech Bull 3X Shares (NYSEARCA: LABU) if you want a speculative play in the biotechnology industry with amplified volatility. This ETF attempts to mimic 3X the one-day performance of the SPDR S&P 500 Biotech ETF (NYSE: XBI). Remember the keyword "attempts... Read the Full Story |
|
Technology | |
Legendary fund manager Peter Lynch became famous for an investment strategy called Growth at a Reasonable Price (GARP). While Lynch retired as manager of the Fidelity Magellan Fund in 1990 at only 46 (a testament to his success), the GARP strategy is still valid and can be applied today to stocks... Read the Full Story |
|
Consumer Staples | |
Backed by the U.S. government, the closely watched 10-year Treasury note offers a high degree of safety that stocks and other investments can’t match. What they no longer offer, however, is a 4% annualized interest rate.
Since the Silicon Valley Bank collapse, Treasury rates have been in a ... Read the Full Story |
|
Technology | |
The semiconductor industry has become a breeding ground for political battles and market share domination across the globe. The United States and China have entered into a cold war-like scenario over who gets to make the most advanced chips and who gets to make the most in volume.
Companies like ... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California. | | View Today's Stock Pick |
|
